Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 | Zendy

Evanthia Galanis | Zendy; S. Keith Anderson | Zendy; C. Ryan Miller | Zendy; Jann N. Sarkaria | Zendy; Kurt A. Jaeckle | Zendy; Jan C. Buckner | Zendy; Keith L. Ligon | Zendy; Karla V. Ballman | Zendy; Dennis F. Moore | Zendy; Michael Nebozhyn | Zendy; Andrey Loboda | Zendy; David Schiff | Zendy; Manmeet S. Ahluwalia | Zendy; Eudocia Q. Lee | Zendy; Elizabeth R. Gerstner | Zendy; Glenn J. Lesser | Zendy; Michael D. Prados | Zendy; Stuart A. Grossman | Zendy; Jane Cerhan | Zendy; Caterina Giannini | Zendy; Patrick Y. Wen | Zendy

Open Access

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Author(s) -

Evanthia Galanis,

S. Keith Anderson,

C. Ryan Miller,

Jann N. Sarkaria,

Kurt A. Jaeckle,

Jan C. Buckner,

Keith L. Ligon,

Karla V. Ballman,

Dennis F. Moore,

Michael Nebozhyn,

Andrey Loboda,

David Schiff,

Manmeet S. Ahluwalia,

Eudocia Q. Lee,

Elizabeth R. Gerstner,

Glenn J. Lesser,

Michael D. Prados,

Stuart A. Grossman,

Jane Cerhan,

Caterina Giannini,

Patrick Y. Wen

Publication year - 2017

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/nox161

Subject(s) - temozolomide , vorinostat , medicine , glioblastoma , radiation therapy , alliance , oncology , cancer research , geography , biology , biochemistry , histone deacetylase , gene , histone , archaeology

Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research